EDDING GENOR (06998) announced its annual results for the year ended December 31, 2025. The Group recorded revenue of RMB 2.487 billion, representing a decrease of 2.3% compared to the previous year. Profit attributable to owners of the parent was RMB 399 million, an increase of 2.93% year-on-year. Basic earnings per share were 23.8 fen.
In 2025, the total sales revenue from the innovative drug Vespair® reached RMB 189 million, an increase of RMB 112 million from 2024, representing a growth of 144.0%. The company intensified its sales and promotion efforts for Vespair®, driving its strong sales performance.
Conversely, in 2025, the total sales revenue for Venocard® decreased by RMB 110 million compared to the previous year, a decline of 46.1%. The primary reason was that all products in the Popa category were in a market adjustment phase in 2025, leading to an overall decrease in end-market demand.
Revenue from Cefaclor® was RMB 264 million in the first half of the year and RMB 543 million in the second half. Compared to the first half of 2025, Cefaclor® revenue increased significantly in the second half, while full-year revenue remained largely flat with the previous year, showing a slight decrease. The sales decline of Cefaclor® in the first half of 2025 was mainly due to its retail market being affected by the slowdown in China's antibacterial drug market during that period. Additionally, the Group adjusted its retail sales strategy, prioritizing partnerships with national and regional chain pharmacies and reducing business with small wholesalers. However, with the gradual increase in innovative antibacterial drugs and a slow rise in the prevalence of related indications, the Group's retail business resumed growth in the second half of the year, aligning with the Group's strategic plan. During the reporting period, the average selling price for Cefaclor® remained stable.
Comments